Insmed has announced the termination of its clinical development for Brinsupri (brensocatib) as a treatment for hidradenitis suppurativa. The decision follows a phase 2b trial in which the daily pill failed to outperform a placebo in treating the chronic inflammatory skin disorder according to industry reports.
Although the results for the skin indication were disappointing, the setback does not appear to diminish the drug’s primary trajectory. Brinsupri remains positioned as a potential blockbuster therapy for non-cystic fibrosis bronchiectasis, a chronic lung condition for which it is the first approved therapy.
For patients and clinicians, this development highlights the complex nature of drug development, where a single molecule may show significant efficacy in one organ system—such as the lungs—while failing to meet clinical endpoints in another, like the skin.
Understanding the Trial Failure in Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic, often painful inflammatory skin disease characterized by nodules, abscesses, and scarring. Because of its debilitating nature, there is a constant demand for new therapeutic options. Insmed sought to determine if Brinsupri, a DPP1 inhibitor, could provide a viable treatment path for those suffering from this condition.
However, the mid-stage clinical trial did not yield the necessary results. The drug failed to beat the placebo, leading the company to discontinue the development of Brinsupri for this specific indication as reported by MSN. In the pharmaceutical industry, a “failed” trial at this stage typically means the drug did not meet its primary endpoint—the specific goal defined at the start of the study to prove the drug works better than no treatment at all.
What is a DPP1 Inhibitor?
Brinsupri functions as a DPP1 inhibitor. Dipeptidyl peptidase 1 (DPP1) is an enzyme involved in the activation of serine proteases, which play a role in inflammation. By inhibiting this enzyme, the drug aims to reduce the inflammatory response in the body. While this mechanism was hypothesized to be effective for the skin inflammation seen in HS, the clinical data indicated it was not sufficient to provide a therapeutic benefit over a placebo according to MedCity News.
The Shift Toward Respiratory Success
Despite the disappointment in the dermatology space, the outlook for Brinsupri in respiratory health remains strong. The drug is projected to be a blockbuster seller in the treatment of non-cystic fibrosis bronchiectasis (NCFB).
NCFB is a chronic lung condition where the bronchial tubes become permanently widened and damaged, leading to a cycle of inflammation and infection. Brinsupri is notable for being the first approved therapy for this specific chronic lung condition. The ability of the drug to target the inflammatory pathways in the lungs appears to be its most promising application, ensuring that the company’s overall goals for the molecule remain intact despite the skin-trial failure.
Why the Difference in Outcomes?
It is not uncommon for a drug to succeed in one therapeutic area while failing in another. The biological environment of the lungs differs significantly from that of the skin. The specific way DPP1 inhibition interacts with the immune response in the respiratory tract may be more potent or relevant than its interaction within the dermal layers. This divergence is why the failure in the HS study is not viewed as a “dent” in the drug’s potential for treating bronchiectasis.
Key Takeaways for Patients and Investors
- Development Halted: Insmed has officially ended the development of Brinsupri for hidradenitis suppurativa following a failed phase 2b trial.
- Placebo Performance: The drug failed to show a statistically significant improvement over the placebo in the mid-stage skin study.
- Lung Potential: Brinsupri remains the first approved therapy for non-cystic fibrosis bronchiectasis and is expected to perform well in this market.
- Mechanism: As a DPP1 inhibitor, the drug targets chronic inflammation, though its efficacy varies by the condition being treated.
For those following the progress of Insmed (INSM), the focus now shifts entirely toward the commercial rollout and long-term monitoring of Brinsupri’s performance in respiratory care. The company’s strategic decision to cut losses on the skin indication allows them to concentrate resources on the area where the drug has already demonstrated success.
As a physician and journalist, I find this a textbook example of the “fail swift” mentality in medical innovation. By identifying the lack of efficacy in HS early in the mid-stage process, the company avoids the massive expense of a failed Phase 3 trial, preserving capital for the bronchiectasis pipeline.
The next official updates regarding Brinsupri’s market performance and regulatory milestones in the respiratory space are expected in upcoming company filings and clinical reports. We encourage our readers to share this update and leave their thoughts on the future of targeted inflammation therapies in the comments below.